SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending as a low-float oil play amidst escalating geopolitical tensions in the Middle East and reports of disrupted shipping through the Strait of Hormuz. The community is actively discussing its potential for a significant run and short squeeze, drawing comparisons to past surges during global conflicts.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as escalating US-Iran hostilities, including reported strikes on oil infrastructure and US casualties, have ignited a sharp debate among investors; some predict a significant market downturn while others anticipate a "buy the dip" rally, driven by concerns over spiking oil prices and tech sector valuations.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amidst escalating Middle East tensions as investors debate the impact of US and Israeli strikes on Iran, with some bracing for market drawdowns and oil shocks while others expect a 'buy the dip' rally, arguing the conflict is already priced in or will ultimately lead to regional stability.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp is trending as escalating Middle East tensions and concerns over the Strait of Hormuz are fueling broad interest in oil and gas plays, with the community discussing its low float, high short interest, and recent balance sheet improvements as catalysts for a potential squeeze.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending as its recent sharp decline sparks vigorous debate among investors, who are weighing strong company fundamentals and anticipated S&P 500 inclusion against broader market and financial sector downturns.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending as escalating geopolitical tensions in the Middle East, particularly around the Strait of Hormuz, drive a significant oil price surge and broad community discussion on energy stocks. Investors are actively positioning in XOM, anticipating further upside as a hedge against potential global supply disruptions.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is trending amid escalating geopolitical tensions in the Middle East, with US-Israel strikes on Iran leading to retaliatory actions and significant disruptions to tanker traffic through the Strait of Hormuz. The community is actively discussing a market rotation into energy as a defensive play, anticipating a sustained 'war premium' and rising oil prices due to potential supply shocks and surging shipping costs.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is a focal point of market discussion, as high expectations for surging AI revenue from hyperscaler infrastructure spending ahead of its upcoming earnings report clash with broader sentiment around chip valuations and geopolitical uncertainties.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid heightened geopolitical tensions driving speculation in defense drone stocks, with the community actively anticipating potential significant contract awards from the Drone Dominance Program and the upcoming US Army UAS Marketplace Showcase.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is trending due to its definitive merger agreement with Coterra Energy, set to create a major U.S. shale producer with increased scale and significant cost synergies, while also fueling community discussion around an enhanced dividend and substantial share repurchase program. Investors are also closely watching its Q4 earnings results and the broader impact of fluctuating oil prices amidst geopolitical developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Zen Downgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold

Wall Street Zen cut shares of Akebia Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...

Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results, Misses Expectations By $0.02 EPS

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts...

<ul class="summary-bullets"><li>Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS).</li><li>In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.</li><li>The company ended Q4 with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.</li></ul>&nbsp;Shares of Akebia Therapeutics Inc (AKBA) rose 7% on Thursday after the company announced that it expects significant revenue growth for its approved anemia medicine Vafseo in 2026 while it also advances its clinical pipeline.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-reports-fourth-quarter-and-full-year-2025">said</a> on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027. Akebia acquired the experimental drug from Q32 Bio in November. The company will explore the drug in IgA nephropathy, lupus nephritis and C3 glomerulopathy, it said.Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS). Target enrollment for the trial is approximately 60 patients.<h2 class="st-heading-2">Future Of FDA-Approved Medicines</h2>Akebia has two medicines approved by the U.S. Food and Drug Administration including <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Vafseo </a>for the treatment of anemia due to chronic kidney disease (CKD) in dialysis patients. In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.“Vafseo commercial trends are showing marked improvement in early 2026... Patient access to Vafseo therapy now stands at 290,000 patients, and early data points to improved patient adherence rates, which we believe are enhanced as a result of dialysis organizations deciding to implement observed dosing protocols. These dynamics, along with the building evidence of clinical differentiation, are expected to drive significant Vafseo revenue growth in 2026 and beyond…, ” said CEO John P. Butler.<h2 class="st-heading-2">Q4 Numbers</h2>For the fourth quarter, the company reported net product revenues of $54.3 million, owing to a quarter-on-quarter increase in prescribers for Vafseo which was launched in the U.S. in Jan. 2025 and an increase in sales volume for Auryxia. Analysts on average were expecting the company to report revenue of $46.09 million.Net loss per share for the period came in at $0.05, compared to a loss of $0.10 in the corresponding quarter of 2024, but above an analyst estimate of a loss of $0.04.The company ended the quarter with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AKBA stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user highlighted the several potential catalysts for the stock including accelerating adoption for Vafseo and cash hoard.<stembedurl>https://www.stocktwits.com/ROCKET123/message/645988666</stembedurl>Another voiced hopes for stock as much as doubling “sooner or later.”<stembedurl>https://www.stocktwits.com/Andi77/message/645980832</stembedurl><a href="https://stocktwits.com/symbol/AKBA">AKBA stock</a> has fallen 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-falls-michael-burry-says-nvidia-purchase-commitments-akin-to-cisco-dot-com-bubble/cZTGi6FRIRb">Michael Burry Warns Nvidia’s ‘Purchase Commitments’ Akin To Cisco At The Top Of Dot-Com Bubble — NVDA Stock Falls 5%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Akebia Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.

Equity

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.


Akebia Therapeutics Q4 Earnings Call Highlights

Akebia Therapeutics (NASDAQ:AKBA) executives used the company's fourth-quarter 2025 earnings call to review the first full year of Vafseo's U.S. launch, discuss efforts to build clinical and economic...

Akebia Therapeutics, Inc. Q4 Loss Decreases

(RTTNews) - Akebia Therapeutics, Inc. (AKBA) revealed Loss for fourth quarter of -$12.24 million...

Akebia Therapeutics Q4 Earnings Report: What Investors Need to Know

Uncovering Potential: Akebia Therapeutics's Earnings Preview

BTIG Research Has Lowered Expectations for Akebia Therapeutics (NASDAQ:AKBA) Stock Price

BTIG Research lowered their target price on Akebia Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Wednesday...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, MarketBeat...

Akebia Therapeutics (AKBA) to Release Quarterly Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Akebia Therapeutics Inc.

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

AKBA
Akebia Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AKBA News

AKBAAkebia Therapeutics Inc.